Centocor has been a leader in biotechnology since the late 1970s. The company is a market leader in acute coronary care with ReoPro® (abciximab) which was the first drug in its class to be introduced. It is available worldwide and is indicated as an adjunct to percutaneous coronary intervention (PCI) to prevent cardiac ischemic complications in patients undergoing percutaneous coronary intervention (PCI), as well as in unstable angina patients not responding to conventional medical therapy when PCI is planned within 24 hours. PCI includes balloon angioplasty, atherectomy and stent placement. |
